Investors

Bioasis Technologies, Inc. is a science-driven company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Our goal is to generate shareholder value by developing and commercializing our proprietary brain delivery technology, xB3, to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.

BTI.V
loading
loading
loading
Today's Open:
loading
Previous Close:
loading
High:
loading
Low:
loading
Volume:
loading

All Public Filings (Canada)

Most Recent Financial Reports (US)

Corporate Presentation

Investor News and Events

  • Oct. 30, 2018 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited… Read more »

  • Oct. 29, 2018 Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

    Under the terms of the agreement, Bioasis to receive a US$1 million upfront payment from Prothena, plus additional potential option exercise, regulatory and commercial milestone payments, plus additional royalties on net sales from licensed products Prothena will receive a worldwide, exclusive license to use the xB 3  platform with an undisclosed neurodegenerative disease target as well as the option for three additional neuroscience targets

  • Oct. 4, 2018 Bioasis Announces Investor Relations Service Agreement with Stern IR

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has engaged Stern Investor Relations, Inc. (“Stern… Read more »

All Events and Presentations